Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
- PMID: 37229695
- DOI: 10.1093/cid/ciad319
Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Abstract
The Infectious Diseases Society of America and the American Association for the Study of Liver Diseases have collaboratively developed evidence-based guidance regarding the diagnosis, management, and treatment of hepatitis C virus (HCV) infection since 2013. A panel of clinicians and investigators with extensive infectious diseases or hepatology expertise specific to HCV infection periodically review evidence from the field and update existing recommendations or introduce new recommendations as evidence warrants. This update focuses on changes to the guidance since the previous 2020 published update, including ongoing emphasis on recommended universal screening; management recommendations for incomplete treatment adherence; expanded eligibility for simplified chronic HCV infection treatment in adults with minimal monitoring; updated treatment and retreatment recommendations for children as young as 3 years old; management and treatment recommendations in the transplantation setting; and screening, treatment, and management recommendations for unique and key populations.
Keywords: HCV guidance; HCV prevention; HCV screening; HCV treatment; direct-acting antivirals.
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Comment in
-
Revamping hepatitis C global eradication efforts: towards simplified and enhanced screening, prevention, and treatment.Transl Gastroenterol Hepatol. 2024 Mar 15;9:30. doi: 10.21037/tgh-23-104. eCollection 2024. Transl Gastroenterol Hepatol. 2024. PMID: 38716222 Free PMC article. No abstract available.
Similar articles
-
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.Clin Infect Dis. 2018 Oct 30;67(10):1477-1492. doi: 10.1093/cid/ciy585. Clin Infect Dis. 2018. PMID: 30215672 Free PMC article.
-
Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.MMWR Recomm Rep. 2009 Sep 4;58(RR-11):1-166. MMWR Recomm Rep. 2009. PMID: 19730409 Free PMC article.
-
Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines.JHEP Rep. 2021 Jan 15;3(2):100227. doi: 10.1016/j.jhepr.2021.100227. eCollection 2021 Apr. JHEP Rep. 2021. PMID: 33665586 Free PMC article.
-
Management of acute HCV infection in the era of direct-acting antiviral therapy.Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):412-424. doi: 10.1038/s41575-018-0026-5. Nat Rev Gastroenterol Hepatol. 2018. PMID: 29773899 Review.
-
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714 Review.
Cited by
-
New perspectives in hepatocellular carcinoma surveillance after hepatitis C virus eradication.Gastroenterol Rep (Oxf). 2024 Sep 23;12:goae085. doi: 10.1093/gastro/goae085. eCollection 2024. Gastroenterol Rep (Oxf). 2024. PMID: 39319076 Free PMC article. Review.
-
Hepatitis C in Children-An Asia-Pacific Concise Perspective.Pathogens. 2024 Oct 1;13(10):860. doi: 10.3390/pathogens13100860. Pathogens. 2024. PMID: 39452731 Free PMC article. Review.
-
The usefulness of anti-HCV signal to cut-off ratio in predicting hepatitis C viremia and the effect of genotype differences on signal to cut-off ratio.Rev Assoc Med Bras (1992). 2024 Sep 2;70(8):e20240370. doi: 10.1590/1806-9282.20240370. eCollection 2024. Rev Assoc Med Bras (1992). 2024. PMID: 39230144 Free PMC article.
-
An Increase in the Prevalence of Clinically Relevant Resistance-Associated Substitutions in Four Direct-Acting Antiviral Regimens: A Study Using GenBank HCV Sequences.Pathogens. 2024 Aug 9;13(8):674. doi: 10.3390/pathogens13080674. Pathogens. 2024. PMID: 39204274 Free PMC article.
-
Self-reported hepatitis B testing among noninstitutionalized adults in the United States before the implementation of universal screening, 2013-2017: A nationwide population-based study.J Viral Hepat. 2024 Nov;31(11):657-669. doi: 10.1111/jvh.13985. Epub 2024 Jul 30. J Viral Hepat. 2024. PMID: 39078109
LinkOut - more resources
Full Text Sources
